Stock Events

Stock Events

Kura Oncology 

$10.39
52
-$0.06-0.57% Friday 20:00
+$0.12+1.11%Friday 23:47After hours

Statistics

Day High
10.4
Day Low
10.39
52W High
12.49
52W Low
5.45
Volume
30,927
Avg. Volume
-
Mkt Cap
922.37M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.88
-0.66
-0.44
-0.22
Expected EPS
-0.877326
Actual EPS
N/A

Financials

-412.95%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
67.48MRevenue
-278.67MNet Income

Analyst Ratings

24.60Average Price Target
The highest estimate is 36.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KURA. It's not an investment recommendation.
Microsoft
12
MSFT
NVIDIA
11
NVDA
Alphabet
10
GOOGL
AMD
10
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences has a strong portfolio in oncology and hematology, making it a direct competitor in cancer treatment.
Incyte
INCY
Mkt Cap23.32B
Incyte Corporation specializes in oncology products, competing in similar markets as Kura Oncology.
Merck
MRK
Mkt Cap305.12B
Merck & Co. has a broad oncology portfolio, including therapies that could compete with Kura Oncology's treatments.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb offers a wide range of cancer treatments, posing competition to Kura Oncology's product pipeline.
Novartis
NVS
Mkt Cap293.94B
Novartis AG has extensive research and development in oncology, competing with Kura Oncology in developing cancer therapies.
AMGEN
AMGN
Mkt Cap196.12B
Amgen focuses on human therapeutics, including oncology, which puts it in competition with Kura Oncology.
Pfizer
PFE
Mkt Cap137.76B
Pfizer has a significant presence in oncology, making it a competitor in the cancer treatment market.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its pharmaceuticals division, competes in the oncology space, offering treatments that could rival Kura Oncology's.

About

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Show more...
CEO
Dr. Troy Edward Wilson J.D., Ph.D.
Employees
260
Country
United States
ISIN
US50127T1097

Listings

STU
DE
KUR.STU
XNAS
US
KURA
BOATS
BOATS
KURA.BOATS
F
DE
KUR.F

0 Comments

Share your thoughts

FAQ

What is Kura Oncology stock price today?▼
The current price of KURA is $10.39 USD — it has decreased by -0.57% in the past 24 hours. Watch Kura Oncology stock price performance more closely on the chart.
What is Kura Oncology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Kura Oncology stocks are traded under the ticker KURA.
Is Kura Oncology stock price growing?▼
KURA stock has fallen by -4.33% compared to the previous week, the month change is a -4.68% fall, over the last year Kura Oncology has showed a +66.77% increase.
What is Kura Oncology market cap?▼
Today Kura Oncology has the market capitalization of 922.37M
When is the next Kura Oncology earnings date?▼
Kura Oncology is going to release the next earnings report on July 30, 2026.
What were Kura Oncology earnings last quarter?▼
KURA earnings for the last quarter are -0.83 USD per share, whereas the estimation was -0.83 USD resulting in a +0.54% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Kura Oncology revenue for the last year?▼
Kura Oncology revenue for the last year amounts to 67.48M USD.
What is Kura Oncology net income for the last year?▼
KURA net income for the last year is -278.67M USD.
How many employees does Kura Oncology have?▼
As of July 26, 2026, the company has 260 employees.
In which sector is Kura Oncology located?▼
Kura Oncology operates in the Health & Wellness sector.
When did Kura Oncology complete a stock split?▼
Kura Oncology has not had any recent stock splits.
Where is Kura Oncology headquartered?▼
Kura Oncology is headquartered in San Diego, United States.